We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

114 hedge funds and large institutions have $137M invested in Neumora Therapeutics in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

48% more call options, than puts

Call options by funds: $2.68M | Put options by funds: $1.81M

22% more capital invested

Capital invested by funds: $113M → $137M (+$24.6M)

12% more funds holding

Funds holding: 102 → 114 (+12)

4.46% more ownership

Funds ownership: 37.67% → 42.13% (+4.5%)

6% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 32

Holders
114
Holders Change
+12
Holders Change %
+11.76%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
24
Increased
34
Reduced
32
Closed
10
Calls
$2.68M
Puts
$1.81M
Net Calls
+$863K
Net Calls Change
-$433K

Top Buyers

1
PA
Perceptive Advisors
New York
+$13.2M
2
SL
Siren LLC
Connecticut
+$5.72M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.59M
4
SCM
Silverarc Capital Management
Massachusetts
+$2.12M
5
Tudor Investment Corp
Tudor Investment Corp
Connecticut
+$2M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.96M
2
Millennium Management
Millennium Management
New York
-$2.23M
3
TCM
Tang Capital Management
California
-$1.37M
4
Jane Street
Jane Street
New York
-$988K
5
SoftBank Group
SoftBank Group
Japan
-$880K
Name Holding Trade Value Shares
Change 		Change in
Stake
SL
1
Siren LLC
Connecticut
$16.6M +$5.72M +2,209,039 +35%
SoftBank Group
2
SoftBank Group
Japan
$11.9M -$880K -339,419 -5%
PA
3
Perceptive Advisors
New York
$9.95M +$13.2M +5,104,097 New
MCMU
4
MIC Capital Management (UK)
United Kingdom
$8.7M – – –
VCM
5
Vanguard Capital Management
Pennsylvania
$7.59M +$10.1M +3,891,893 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$6.82M +$1.01K +389 +0%
WT
7
Wellcome Trust
United Kingdom
$6.45M – – –
Millennium Management
8
Millennium Management
New York
$5.37M -$2.23M -861,660 -24%
IC
9
Iconiq Capital
California
$4.99M – – –
LC
10
Lunate Capital
United Arab Emirates
$4.14M – – –
BlackRock
11
BlackRock
New York
$4.01M +$76.1K +29,372 +1%
Two Sigma Investments
12
Two Sigma Investments
New York
$3.97M +$1.89M +729,004 +56%
JJ
13
Johnson & Johnson
New Jersey
$3.61M – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$2.71M -$147K -56,904 -4%
IC
15
Ikarian Capital
Texas
$2.49M – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$2.42M +$1.3M +501,969 +68%
Marshall Wace
17
Marshall Wace
United Kingdom
$2.33M +$1.58M +611,552 +105%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.12M +$215K +83,119 +8%
Adage Capital Partners
19
Adage Capital Partners
Massachusetts
$1.95M +$2.59M +1,000,000 New
SCM
20
Silverarc Capital Management
Massachusetts
$1.6M +$2.12M +818,156 New
Tudor Investment Corp
21
Tudor Investment Corp
Connecticut
$1.5M +$2M +771,418 New
Jane Street
22
Jane Street
New York
$1.46M -$988K -381,307 -34%
AC
23
AlphaCore Capital
California
$1.25M – – –
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$1.17M -$7.96M -3,071,436 -84%
Goldman Sachs
25
Goldman Sachs
New York
$1.11M -$752K -290,222 -34%
1
2 3 4 5

NMRA Hedge Fund Activity: Q1 2026 in Review

114 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2026, worth a combined $137M — up 22% from $113M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new NMRA positions and 10 closed out — a net gain of 14 holders — while 34 added to existing stakes and 32 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $13.2M. The largest seller was Point72 Asset Management, cutting an estimated $7.96M.

  • 114 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2026, up from 102 in Q4 2025.
  • Funds reported $137M of Neumora Therapeutics stock for Q1 2026, up 22% quarter-over-quarter.
  • 24 funds opened new Neumora Therapeutics positions in Q1 2026 and 10 closed out, a net change of +14 holders.
  • The largest Neumora Therapeutics buyer in Q1 2026 was Perceptive Advisors, an estimated $13.2M added.
  • The largest Neumora Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $7.96M sold.

Based on aggregated 13F filings for Q1 2026.